Revenues for the first fiscal quarter of 2025 were $13.7 million, compared to $16.9 million in the first fiscal quarter of 2024, a decrease of 19%. The decrease in revenue for the year was due to ...
Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United Kingdom (UK) for the first authorized use of an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback